Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 4/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.41 |
| ▸ | PRLHR | P49683 | 4/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.40 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351354 | 0.93 | ENPP2 (0.47) | MAPK10MAPK8ENPP2ATXN2CYP2C9 | |
| SCHEMBL349265 | 0.92 | MAPT (0.41) | ENPP2ATXN2POLBNAMPTMEN1 | |
| SCHEMBL351894 | 0.90 | MAPK10 (0.44) | MAPK10MAPK8PRLHRENPP2ATXN2 | |
| SCHEMBL349743 | 0.90 | ENPP2 (0.37) | MAPK10MAPK8PRLHRENPP2ATXN2 | |
| SCHEMBL351047 | 0.88 | ENPP2 (0.34) | MAPK10MAPK8ENPP2ATXN2CYP2C9 | |
| SCHEMBL350051 | 0.88 | ROCK2 (0.39) | MAPK10MAPK8ENPP2ATXN2 | |
| SCHEMBL350624 | 0.87 | MAPK8 (0.46) | MAPK10MAPK8ENPP2ATXN2CYP2C9 | |
| SCHEMBL350573 | 0.87 | NAMPT (0.40) | MAPK10MAPK8PRLHRENPP2ATXN2 | |
| SCHEMBL351126 | 0.86 | ITGB2 (0.39) | PRLHRENPP2ATXN2 | |
| SCHEMBL16817258 | 0.86 | PRLHR (0.41) | MAPK10MAPK8PRLHRENPP2ATXN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414346-B1 | AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | claimed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | claimed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | claimed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | claimed |
| EP-2414346-B1 | AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | MAPK10 1071/4885MAPK8 3052/4885PRLHR 2735/4885 |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | MAPK10 1071/4885MAPK8 3052/4885PRLHR 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.